Table 1 Baseline clinical characteristics before sorafenib treatment and response rates after treatment
Characteristics before sorafenib treatment (n = 132) | Values* |
|---|---|
Age, years | 59 (50–72) |
Male, n (%) | 96 (73) |
Age > 60 years, n (%) | 59 (45) |
Nephrectomy, n (%) | 132 (100) |
Stage at RCC diagnosis, n (%) | |
Unknown | 32 (24) |
1 | 4 (3) |
2 | 11 (8) |
3 | 32 (24) |
4 | 53 (41) |
Karnofsky performance status scores | |
100 | 1 (1) |
90 | 82 (62) |
80 | 49 (37) |
High blood pressure, n (%) | 44 (33) |
Hypothyroidism, n (%) | 8 (6) |
Site of metastasis | |
Lung, n (%) | 70 (53) |
Bone, n (%) | 17 (13) |
Liver, n (%) | 18 (14) |
Lymph node, n (%) | 12 (9) |
First-line and concomitant treatments | |
Sunitinib, n (%) | 132 (100) |
Interferon, n (%) | 3 (2) |
Radiotherapy, n (%) | 27 (20) |
Zoledronic acid, n (%) | 2 (2) |
Risk status, % (n)** | |
Favorable risk | 48 (36) |
Intermediate risk | 81 (61) |
High risk | 3 (23) |
Hemoglobin, g/dL | 13.9 ± 1.8 |
Leucocytes, 109/L | 6.5 (5.3–8.2) |
Neutrophils, 109/L | 3.9 (2.6–5.0) |
Platelets, 109/L | 235 (186–310) |
Albumin-adj calcium, g/dL | 9.5 (9.0–9.8) |
LDH, mg/dL | 178 (151–234) |
Response rates after sorafenib treatment | |
Complete Response, n (%) | 3 (2) |
Partial Response, n (%) | 11 (8) |
Stable Disease, n (%) | 13 (10) |
Progressive Disease, n (%) | 105 (80) |